STAT

Opinion: What record-high funding for neglected diseases doesn’t tell us about R&D for them

Recent investments into neglected diseases research have provided many opportunities to save millions of lives and cast some of the world’s oldest and deadliest diseases into the ash bin of…

In recent weeks, scientists have raced to understand the deadly new coronavirus and develop new tools to diagnose and contain it. As with past emerging threats, I’ve been impressed to see how this novel virus has mobilized collective action that transcends borders, sectors, and individual interests over such a short period.

During those same few weeks, more familiar pathogens have been quietly exacting a far heavier toll on human health and prosperity. like diarrheal illnesses, tuberculosis, malaria, and pneumonia kill thousands of people every day. But because they have been doing so for decades, they simply don’t catalyze the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks